Top-Rated StocksTop-RatedNASDAQ:DXCM DexCom (DXCM) Stock Price, News & Analysis $79.95 -0.22 (-0.27%) Closing price 04:00 PM EasternExtended Trading$79.94 -0.01 (-0.01%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About DexCom Stock (NASDAQ:DXCM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DexCom alerts:Sign Up Key Stats Today's Range$79.87▼$81.5650-Day Range$75.46▼$89.5352-Week Range$57.52▼$93.25Volume4.07 million shsAverage Volume3.91 million shsMarket Capitalization$31.35 billionP/E Ratio55.52Dividend YieldN/APrice Target$99.89Consensus RatingModerate Buy Company Overview DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California. Read More DexCom Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks98th Percentile Overall ScoreDXCM MarketRank™: DexCom scored higher than 98% of companies evaluated by MarketBeat, and ranked 30th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingDexCom has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 15 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageDexCom has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about DexCom's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth21.18% Earnings GrowthEarnings for DexCom are expected to grow by 21.18% in the coming year, from $2.03 to $2.46 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DexCom is 55.52, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.72.Price to Earnings Ratio vs. SectorThe P/E ratio of DexCom is 55.52, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 30.05.Price to Earnings Growth RatioDexCom has a PEG Ratio of 1.63. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDexCom has a P/B Ratio of 12.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DexCom's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.27% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently decreased by 15.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDexCom does not currently pay a dividend.Dividend GrowthDexCom does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.76 Percentage of Shares Shorted2.27% of the outstanding shares of DexCom have been sold short.Short Interest Ratio / Days to CoverDexCom has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in DexCom has recently decreased by 15.41%, indicating that investor sentiment is improving significantly. News and Social Media4.0 / 5News Sentiment1.24 News SentimentDexCom has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 29 news articles for DexCom this week, compared to 25 articles on an average week.Search Interest23 people have searched for DXCM on MarketBeat in the last 30 days. This is an increase of 156% compared to the previous 30 days.MarketBeat Follows8 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,412,191.00 in company stock.Percentage Held by InsidersOnly 0.32% of the stock of DexCom is held by insiders.Percentage Held by Institutions97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about DexCom's insider trading history. Receive DXCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter. Email Address DXCM Stock News HeadlinesInsider Selling: DexCom, Inc. (NASDAQ:DXCM) EVP Sells 1,466 Shares of StockJuly 30, 2025 | insidertrades.com5 Revealing Analyst Questions From DexCom’s Q2 Earnings CallAugust 13 at 8:48 AM | finance.yahoo.com7 High-Yield Dividend Stocks You Need to See7 High Yield Dividend Stocks to Buy Now 💰 Love steady payouts? This free report reveals 7 high-yield dividend stocks you need to know about. From Company #3, a tobacco giant innovating with smokeless products, to Company #4, famously known as “The Monthly Dividend Company,” these picks deliver steady income you can count on.August 13 at 2:00 AM | TradingTips (Ad)DXCM Q2 CY2025 Deep Dive: Volume Growth, Leadership Changes, and New Product Launches Shape OutlookAugust 13 at 8:48 AM | finance.yahoo.comLombard Medical (OTCMKTS:EVARF) and DexCom (NASDAQ:DXCM) Head to Head SurveyAugust 13 at 2:15 AM | americanbankingnews.comDexCom (NASDAQ:DXCM) Stock Rating Lowered by Wall Street ZenAugust 12 at 2:19 AM | americanbankingnews.comDEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. ...August 6, 2025 | gurufocus.comDEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmAugust 6, 2025 | globenewswire.comSee More Headlines DXCM Stock Analysis - Frequently Asked Questions How have DXCM shares performed this year? DexCom's stock was trading at $77.77 at the beginning of the year. Since then, DXCM shares have increased by 2.8% and is now trading at $79.95. How were DexCom's earnings last quarter? DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings data on Wednesday, July, 30th. The medical device company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. DexCom's quarterly revenue was up 15.2% compared to the same quarter last year. Read the conference call transcript. When did DexCom's stock split? DexCom shares split on Friday, June 10th 2022.The 4-1 split was announced on Friday, March 25th 2022. The newly created shares were payable to shareholders after the closing bell on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split. Does DexCom have any subsidiaries? The following companies are subsidiaries of DexCom: TypeZero Technologies Inc, Nintamed Handels GmbH, DexCapital LLC, DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom (Canada) Inc., DexCom Deutschland GmbH, and more. Who are DexCom's major shareholders? DexCom's top institutional investors include Vanguard Group Inc. (12.32%), Jennison Associates LLC (2.94%), Geode Capital Management LLC (2.75%) and Sands Capital Management LLC (2.54%). Insiders that own company stock include Kevin R Sayer, Jacob Steven Leach, Jereme M Sylvain, Steven Robert Pacelli, Sadie Stern, Michael Jon Brown, Barry J Regan, Mark G Foletta, Steven R Altman, Paul R Flynn, Shelly Ramasamy Selvaraj, Matthew Vincent Dolan, Nicholas Augustinos and Bridgette P Heller. View institutional ownership trends. How do I buy shares of DexCom? Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of DexCom own? Based on aggregate information from My MarketBeat watchlists, some other companies that DexCom investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Invesco QQQ (QQQ). Company Calendar Last Earnings7/30/2025Today8/13/2025Next Earnings (Estimated)10/23/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:DXCM CIK1093557 Webwww.dexcom.com Phone(858) 200-0200Fax858-200-0201Employees10,300Year Founded1999Price Target and Rating Average Price Target for DexCom$99.89 High Price Target$115.00 Low Price Target$85.00 Potential Upside/Downside+23.6%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)$1.44 Trailing P/E Ratio56.11 Forward P/E Ratio39.80 P/E Growth1.63Net Income$576.20 million Net Margins13.29% Pretax Margin18.23% Return on Equity30.41% Return on Assets10.08% Debt Debt-to-Equity Ratio0.48 Current Ratio1.52 Quick Ratio1.35 Sales & Book Value Annual Sales$4.03 billion Price / Sales7.86 Cash Flow$2.33 per share Price / Cash Flow34.64 Book Value$6.56 per share Price / Book12.32Miscellaneous Outstanding Shares392,150,000Free Float390,900,000Market Cap$31.69 billion OptionableOptionable Beta1.43 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:DXCM) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DexCom, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DexCom With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.